The effects of three small morning and evening doses of LSD on mood, biological and psychological measures of sleep, neuroplasticity, and well-being

This interventional trial (n=24) conducted by Maastricht University, with support from Mind Medicine Inc. (MindMed), aims to investigate the effects of three small morning and evening doses of LSD (20µg) on mood, sleep parameters, neuroplasticity, cognitive performance, emotion regulation, markers of well-being, cortisol, and endocannabinoid levels in healthy volunteers.

The study follows a double-blinded, randomised controlled trial design, with LSD (20µg) and a placebo administered on three dosing days interspersed with one day for a total of four sessions. The primary objective is to assess the impact of LSD on mood, with secondary objectives focusing on various psychological and physiological measures.

Participants must be at least 18 years old, without major medical or psychological conditions, and willing to adhere to study guidelines. The trial started recruiting on December 1, 2021, and is ongoing. Contact for public inquiries is Eline Haijen at Maastricht University.

Topic Microdosing
Compound LSD
Country Netherlands
Visit trial
Status Recruiting
Results Published No
Start date 01 December 2021
End date 30 December 2024
Phase Not Applicable
Design Blinded
Type Interventional
Generation First
Participants 24
Sex All
Age 18- 99
Therapy No

Trial Details

Primary objective is to investigate the effects of three repeated morning vs evening doses of LSD (20 µg) on mood. Secondary objectives are to investigate the effects of three repeated morning vs evening doses of LSD (20 µg) on neuroplasticity, sleep parameters, cognitive performance measures, emotion regulation, markers of well-being, cortisol, and endocannabinoid levels.

NCT Number NL9821

Sponsors & Collaborators

Maastricht University
Maastricht University is host to the psychopharmacology department (Psychopharmacology in Maastricht) where various researchers are investigating the effects of psychedelics.

MindMed
MindMed is one of the largest companies in the psychedelics space and is developing various psychedelics for mental health disorders.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.